INTRODUCTION {#sec1-1}
============

Despite recent advances in the treatment, the burden of sepsis and septic shock remains high, with an incidence between 11 and 240 per 100,000 population, hospital costs of more than \$20 billion annually in the United States, and a mortality as high as 80%.\[[@ref1][@ref2][@ref3][@ref4][@ref5][@ref6][@ref7][@ref8][@ref9][@ref10][@ref11][@ref12][@ref13][@ref14][@ref15]\] Among patients admitted to the Intensive Care Unit (ICU), acute respiratory distress syndrome (ARDS) is a leading cause of increased mortality and long-term reduction in quality of life.\[[@ref16][@ref17][@ref18]\] Despite the great burden of sepsis and ARDS, very few effective strategies are available for treatment.\[[@ref16][@ref17][@ref18][@ref19]\]

Platelets are a vital component of normal hemostasis as well as pathological thrombosis. Antiplatelet therapy (APT) works by interfering with one of the several steps of platelet activation including adhesion, release, and/or aggregation.\[[@ref20]\] While the benefit of APT is well established for primary and secondary prevention of cardiovascular and cerebrovascular diseases,\[[@ref21]\] recent studies have revealed that these agents may also benefit patients with serious infections, sepsis, and those who are admitted to the ICU.\[[@ref22][@ref23][@ref24][@ref25][@ref26][@ref27][@ref28][@ref29][@ref30][@ref31][@ref32][@ref33][@ref34][@ref35]\]

Platelets play an important role in the inflammatory cascade that results in the development of ARDS.\[[@ref36][@ref37][@ref38]\] Observational studies suggest that prehospital use of APT may be protective against the development of ARDS. In addition, data also suggests that these agents may be of benefit in patients with existing ARDS.\[[@ref22]\]

In light of this data, potential use of APT in reducing length of stay and mortality in these patients carries significant weight and has global health and economic ramifications. Given the possible benefit of antiplatelet agents as described in observational data, we aimed to perform a systematic review of literature and meta-analysis to further study the efficacy of these agents in critically ill patients.

MATERIALS AND METHODS {#sec1-2}
=====================

Search strategy {#sec2-1}
---------------

A computerized literature search of all publications in the PubMed, Central, Embase, the Cochrane database, ClinicalTrials.gov website, and Google Scholar databases was performed. We also utilized manual searches for article reference lists and conference proceedings. This was last assessed as up-to-date on March 1, 2016.

Search terms included varying combinations of the following: "ICU," "critical illness," "sepsis," "septic shock," "ARDS," "pneumonia," "infection," "mechanical ventilation," "antiplatelet drugs," "aspirin," "clopidogrel," "prasugrel," "ticlopidine," "cilostazol," "dipyridamole," "tirofiban," eptifibatide," "abciximab," "anagrelide," "ticagrelor," "vorapaxar," "atopaxar," and "Pentoxifylline."

Inclusion criteria {#sec2-2}
------------------

The PRISMA statement of reporting systematic reviews and meta-analysis was applied to the methods for this study \[[Supplementary Table 1](#T1){ref-type="table"}\].\[[@ref40]\]

###### 

PRISMA 2009 checklist

  Section/topic                         Number   Checklist item                                                                                                                                                                                                                                                                                              Reported on page number
  ------------------------------------- -------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------
  Title                                                                                                                                                                                                                                                                                                                                                      
   Title                                1        Identify the report as a systematic review, meta-analysis, or both                                                                                                                                                                                                                                          1
  Abstract                                                                                                                                                                                                                                                                                                                                                   
   Structured summary                   2        Provide a structured summary including as applicable: Background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number   1
  Introduction                                                                                                                                                                                                                                                                                                                                               
   Rationale                            3        Describe the rationale for the review in the context of what is already known                                                                                                                                                                                                                               3
   Objectives                           4        Provide an explicit statement of questions being addressed with reference to PICOS                                                                                                                                                                                                                          4
  Methods                                                                                                                                                                                                                                                                                                                                                    
   Protocol and registration            5        Indicate if a review protocol exists, if and where it can be accessed (e.g., web address), and, if available, provide registration information including registration number                                                                                                                                \-
   Eligibility criteria                 6        Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale                                                                                                       4,5
   Information sources                  7        Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched                                                                                                                                   4
   Search                               8        Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated                                                                                                                                                                                4
   Study selection                      9        State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis)                                                                                                                                                    4,5
   Data collection process              10       Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators                                                                                                                                   4,5
   Data items                           11       List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumption and simplifications made                                                                                                                                                                         4,5
   Risk of bias in individual studies   12       Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis                                                                                       6
   Summary measures                     13       State the principal summary measures (e.g., risk ratio, difference in means)                                                                                                                                                                                                                                6
   Synthesis of results                 14       Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., *I*^2^) for each meta-analysis                                                                                                                                                    6
   Risk of bias across studies          15       Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies)                                                                                                                                                                 6
   Additional analyses                  16       Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were prespecified                                                                                                                                                              6
  Results                                                                                                                                                                                                                                                                                                                                                    
   Study selection                      17       Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram                                                                                                                                              7
   Study characteristics                18       For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations                                                                                                                                                                 7
   Risk of bias within studies          19       Present data on risk of bias of each study and, if available, any outcome level assessment (Item 12)                                                                                                                                                                                                        7
   Results of individual studies        20       For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot                                                                                                     Figures [1](#F1){ref-type="fig"}--[4](#F4){ref-type="fig"}
   Synthesis of results                 21       Present results of each meta-analysis done, including confidence intervals and measures of consistency                                                                                                                                                                                                      7,8
   Risk of bias across studies          22       Present results of any assessment of risk of bias across studies (Item 15)                                                                                                                                                                                                                                  7,8
   Additional analysis                  23       Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression \[Item 16\])                                                                                                                                                                                          7,8
  Discussion                                                                                                                                                                                                                                                                                                                                                 
   Summary of evidence                  24       Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policymakers)                                                                                                                          9
   Limitations                          25       Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias)                                                                                                                                                12
   Conclusions                          26       Provide a general interpretation of the results in the context of other evidence, and implications for future research                                                                                                                                                                                      12
  Funding                                                                                                                                                                                                                                                                                                                                                    
   Funding                              27       Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review                                                                                                                                                                   13

PICOS: Participants, interventions, comparisons, outcomes, and study design

The following inclusion criteria were used:

Studies on critically ill patients including: Studies with adult patients admitted to the ICU or postoperative patients or patients admitted to the hospital with serious infections/sepsis/systemic inflammatory response syndrome (SIRS)/septic shockStudies where one or more antiplatelet agents were used: Irreversible COX inhibitor (aspirin); adenosine diphosphate inhibitors (clopidogrel, prasugrel, ticlopidine, and ticagrelor); phosphodiesterase inhibitors (cilostazol, anagrelide, Pentoxifylline); adenosine reuptake inhibitors (dipyridamole); glycoprotein IIb/IIIa inhibitors (tirofiban, eptifibatide, and abciximab); and protease activated receptor-1 antagonist (atopaxar, vorapaxar).

The following exclusion criteria were applied to the search:

Studies with nonhuman participantsStudies which did not have a direct comparison between antiplatelet users and nonantiplatelet usersStudies which did not report one or more of the end-points for this meta-analysis (mortality, ARDS, length of hospital stay, and need for mechanical ventilation)Studies where the drug being studied was not an antiplatelet agent; for example, studies on only nonsteroidal anti-inflammatory drugs (NSAID), antithrombotic agents, and statins. Two reviewers (DM and JS) independently extracted the data from identified studies.

Disagreements were resolved by consensus, or if necessary, by a third party (MA). An attempt was made to obtain data from authors of all ongoing studies which met the search criteria.

Study end-points {#sec2-3}
----------------

The primary outcome of this analysis was all-cause mortality. Secondary outcomes included incidence of acute lung injury (ALI) or ARDS, length of hospital stay, and need for mechanical ventilation. Individual study definitions for ALI, ARDS, and sepsis were used for this meta-analysis \[[Table 1](#T2){ref-type="table"}\].

###### 

Description of included studies

  Author(s)                            Title                                                                                                                                                               Year of publication   Type of study   Number of patients   Inclusion criteria                                                                                                                                                                                                                                                            Primary outcome                                                                                        Type of antiplatelet drug used                                                        Severity scoring                                               Timing of APT                                                                                         Duration of maximum follow-up   Definition of ALI/ARDS                                                                   Definition of sepsis
  ------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------- --------------- -------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------- -------------------------------------------------------------- ----------------------------------------------------------------------------------------------------- ------------------------------- ---------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------
  Winning *et al*.\[[@ref35]\]         Antiplatelet drugs and outcome in severe infection: Clinical impact and underlying mechanisms                                                                       2009                  Observational   224                  Patients who were admitted to the hospital for CAP                                                                                                                                                                                                                            Need for treatment in ICU Length of hospital stay                                                      Aspirin, clopidogrel                                                                  SOFA 2.95±2.03 (control) versus 2.74±1.18 (APT)                Patients on APT for at least 6 months before admission                                                28 days                                                                                                                  
  Winning *et al*.\[[@ref34]\]         Antiplatelet drugs and outcome in mixed admissions to an ICU                                                                                                        2010                  Observational   615                  Patients admitted to the ICU within 24 h after arrival to the hospital                                                                                                                                                                                                        Death during ICU treatment or discharge from ICU                                                       Aspirin, clopidogrel                                                                  APACHE II: 19 (13-19) (control) versus 25 (19-32) (APT)        Patients on APT before admission                                                                      Duration of ICU stay                                                                                                     
  Erlich *et al*.\[[@ref25]\]          Prehospitalization APT is associated with a reduced incidence of ALI                                                                                                2011                  Observational   161                  Age\>18 years+at least one risk factor for ALI (high-risk trauma, aspiration, sepsis, shock, pneumonia, and pancreatitis)                                                                                                                                                     Development of ALI or ARDS during hospitalization                                                      Aspirin, clopidogrel, ticlopidine, cilostazol, dipyridamole, anagrelide, persantine   APACHE III: 39 (27-54) (control) versus 46 (34-57) (APT)       Patients on APT before admission                                                                                                      American- European Consensus Conference criteria\[[@ref40]\]                             
  Lösche *et al*.\[[@ref50]\]          Do aspirin and other antiplatelet drugs reduce the mortality in critically ill patients?                                                                            2012                  Observational   224                  Patients admitted to the hospital with CAP                                                                                                                                                                                                                                    Length of hospital stay Admission to ICU                                                               Aspirin, ticlopidine, clopidogrel                                                     SOFA odds ratio 0.19 (0.04-0.87)                               Patients on APT for at least 6 months before admission                                                Duration of hospital stay                                                                                                
  Lösche *et al*.\[[@ref50]\]          Do Aspirin and other antiplatelet drugs reduce the mortality in critically ill patients?                                                                            2012                  Observational   834                  ICU admission for severe sepsis or septic shock                                                                                                                                                                                                                               ICU mortality                                                                                          Aspirin                                                                               APACHE II: 22.6±9.2 (control) versus 24.1±8.3 (APT)                                                                                                                  Duration of ICU stay                                                                                                     
  Eisen *et al*.\[[@ref24]\]           Acetylsalicylic acid usage and mortality in critically ill patients with the SIRS and sepsis                                                                        2012                  Observational   2890                 Patients admitted to the ICU with SIRS                                                                                                                                                                                                                                        Hospital mortality                                                                                     Aspirin                                                                               APACHE II: 17.78 (control) versus 17.47 (APT)                  Patients on APT in the 24 h period at time of detection of SIRS                                                                                                                                                                America College of Chest Physicians/Society of Critical Care Medicine Consensus Conference criteria\[[@ref48]\]
  Losche *et al*.\[[@ref29]\]          Association of prehospitalization aspirin therapy and ALI: results of a multicenter international observational study of at-risk patients                           2012                  Observational   3855                 Admission to the hospital with the presence of at least one major risk factor for ALI and age\>18 years.(aspiration, pneumonia, sepsis, shock, pancreatitis, high-risk trauma, or high-risk surgery)                                                                          Development of ALI/ARDS during hospitalization                                                         Aspirin                                                                               APACHE II: 9 (5-14) (control) versus 12 (8-16) (APT)           Documentation of use or administration of APT at time of hospital admission                           Duration of hospital stay       American- European Consensus Conference criteria\[[@ref40]\]                             
  Gross *et al*.\[[@ref27]\]           Clopidogrel treatment and the incidence and severity of community acquired pneumonia in a cohort study and meta-analysis of APT in pneumonia and critical illness   2013                  Observational   23,882               Patients who received at least 6 consecutive prescriptions of clopidogrel                                                                                                                                                                                                     Incidence and severity of pneumonia                                                                    clopidogrel                                                                           NA                                                             ≥6 prescription claims of APT                                                                         Duration of hospital stay                                                                                                
  Harr *et al*.\[[@ref28]\]            APT is associated with decreased transfusion- associated risk of lung dysfunction, multiple organ failure, and mortality in trauma patients                         2013                  Observational   839                  Blunt trauma mechanism, ED arrival within 6 h of injury, ED base deficit\>6 mEq/L or ED systolic blood pressure\<90 mm Hg, and a blood product transfusion within the first 12 h of ED arrival                                                                                Lung dysfunction defined by Denver lung dysfunction score of 2 or 3 Denver MOF score (\>3) Mortality   Aspirin, ticlopidine, clopidogrel                                                     NA                                                             Patients on APT before trauma                                                                         28 days                         Denver lung dysfunction score Grades 2 or 3, which corresponds to PaO2:FiO2 ratio\<200   
  Valerio-Rojas *et al*.\[[@ref33]\]   Outcomes of severe sepsis and septic shock patients on chronic antiplatelet treatment: A historical cohort study                                                    2013                  Observational   651                  ≥18 years, diagnosis of severe sepsis or septic shock at the time of ICU admission and use of APT before admission                                                                                                                                                            Hospital mortality                                                                                     Aspirin, clopidogrel, ticlopidine, dipyridamole                                       APACHE III: 55 (42-68) (control) versus 57.5 (46-74.8) (APT)   Patients on APT at time of ICU admission                                                              Duration of hospital stay       American- European Consensus Conference criteria\[[@ref40]\]                             America College of Chest Physicians/Society of Critical Care Medicine Consensus Conference criteria\[[@ref48]\]
  Otto *et al*.\[[@ref31]\]            Effects of low-dose acetylsalicylic acid and atherosclerotic vascular diseases on the outcome in patients with severe sepsis or septic shock                        2013                  Observational   886                  Only patients with severe sepsis/septic shock and minimum ICU stay of 48 h                                                                                                                                                                                                    ICU mortality Discharge from ICU Hospital mortality                                                    Aspirin, clopidogrel                                                                  NA                                                             Patient on APT for at least 2 days during ICU stay                                                    Duration of hospital stay                                                                                                
  Faverio *et al*.\[[@ref26]\]         Antiplatelets improve survival among critically ill mechanically ventilated patients                                                                                2014                  Observational   150                  Critically ill mechanically ventilated patients for 1 day or more managed at a tertiary medical ICU                                                                                                                                                                           Mortality during ICU and hospital stay                                                                 Aspirin, clopidogrel                                                                  APACHE II\>25                                                  Patient on prehospital or in-hospital APT                                                             Duration of hospital stay                                                                                                
  Chen *et al*.\[[@ref23]\]            Prehospital aspirin use is associated with reduced risk of ARDS in critically ill patients: A propensity- adjusted analysis                                         2015                  Observational   1149                 Patient who are 18 years old or older admitted to the medical, surgical, cardiovascular, and trauma ICUs who remained in the ICU for at least 2 days                                                                                                                          ARDS in first 4 days of ICU stay                                                                       Aspirin                                                                               NA                                                             Patients on APT before admission                                                                      Duration of hospital stay       American- European Consensus Conference criteria\[[@ref40]\]                             America College of Chest Physicians/Society of Critical Care Medicine Consensus Conference criteria\[[@ref48]\]
  Tsai *et al*.\[[@ref32]\]            Association of prior antiplatelet agents with mortality in sepsis patients: A nationwide population-based cohort study                                              2015                  Observational   683,421              All patients with a first time discharge diagnosis of sepsis                                                                                                                                                                                                                  In-hospital mortality from sepsis                                                                      Aspirin, clopidogrel, ticlopidine                                                     NA                                                             Patients on APT currently or within 30 days before admission                                                                                                                                                                   ICD 9 code for sepsis
  Mazzeffi *et al*.\[[@ref30]\]        Preoperative aspirin use and lung injury after aortic valve replacement surgery: A retrospective cohort study                                                       2015                  Observational   375                  All adult patients having aortic valve replacement surgery with cardiopulmonary bypass                                                                                                                                                                                        Occurrence of ARDS                                                                                     Aspirin                                                                               NA                                                             Patients receiving preoperative APT                                                                                                   Berlin definition\[[@ref67]\]                                                            
  Boyle *et al*.\[[@ref22]\]           Aspirin therapy in patients with ARDS is associated with reduced ICU mortality: A prospective analysis                                                              2015                  Observational   202                  All adult patients (\>16 years-old) requiring invasive mechanical ventilation                                                                                                                                                                                                 ICU mortality                                                                                          Aspirin                                                                               APACHE II: 18 (13-24) in (control) versus 21 (17-24) (APT)     Patients on prehospital APT, in ICU APT or both                                                       Duration of hospital stay       American- European Consensus Conference criteria\[[@ref40]\]                             
  Al Harbi *et al*.\[[@ref48]\]        Association between aspirin therapy and the outcome in critically ill patients: A nested cohort study                                                               2016                  Observational   763                  ≥18-year-old with expected ICU length of stay of \>48 h. Patients who were pregnant, had do-not-resuscitate status within 24 h of admission, were terminally ill or admitted to the ICU after cardiac arrest, seizures, liver transplantation, or burn injury were excluded   All cause ICU mortality and in-hospital mortality                                                      Aspirin                                                                               APACHE II: 22.9±8.2 (control) versus 26.5±7.2 (APT)            Patients who had either continuation of a pre-ICU prescription or a newly prescribed APT in the ICU   Duration of ICU stay                                                                                                     

CAP: Community-acquired pneumonia, SIRS: Systemic inflammatory response syndrome, APACHE: Acute Physiology and Chronic Health Evaluation, SOFA: Sequential Organ Failure Assessment, APT: Antiplatelet therapy, NA: Not available, ICU: Intensive Care Unit, ALI: Acute lung injury, ARDS: Acute respiratory distress syndrome, ED: Emergency department

In studies where multiple follow-up periods were available, the longest follow-up was included in the analysis.

Study analysis {#sec2-4}
--------------

Data were summarized across treatment arms using the Mantel-Haenszel odds ratio (OR) or standardized mean difference (SMD). We evaluated heterogeneity of effects using the Higgins' *I*^2^ statistic. Fixed effects model was used except in cases where heterogeneity was significant (defined as *I*^2^ \>40%). In these cases, random effects models were used.\[[@ref42]\]

To address publication bias, we used four methods: Funnel plots,\[[@ref43]\] Begg and Mazumdar test,\[[@ref44]\] Egger test,\[[@ref45]\] and Duval and Tweedie\'s test.\[[@ref46]\] Sensitivity analyses were performed using the one-study out method, addressing the influence of each study by testing whether deleting each individually would significantly change the pooled results of the meta-analysis on the final effect and its precision. We also carried out a sensitivity analysis by comparing studies on aspirin with studies where patients were on APT other than aspirin, either alone or in combination with aspirin. Finally, chronological cumulative analyses were used to test if the effect size and precision shifts based on technical advancement in critical care medicine. The statistical analysis was performed by the Comprehensive Meta-Analysis version 2.0 software (Biostat, Inc., New Jersey, USA).

Individual study quality appraisal {#sec2-5}
----------------------------------

Two authors (DM, JS) independently assessed the risk of bias of included studies using the standardized Newcastle-Ottawa scale.\[[@ref47]\] This validated instrument for appraising observational studies measures the risk of bias in eight categories: Representativeness of the exposed cohort (S1); selection of the nonexposed cohort (S2); ascertainment of exposure (S3); demonstration that the outcome of interest was not present at the start of the study (S4); comparability (C1 and C2); assessment of outcome (E1); was follow-up long enough for outcomes to occur (E2); and adequacy of follow-up of cohorts (E3) \[[Supplementary Table 2](#T3){ref-type="table"}\]. Discrepancies were resolved by discussion or adjudication by a third author (MA).

###### 

Newcastle-Ottawa scale for observational studies included in our meta-analysis

  Author(s)                              Selection   Comparability   Exposure   Total stars                      
  -------------------------------------- ----------- --------------- ---------- ------------- --- --- --- --- -- ---
  Winning *et al*.\[[@ref35]\]           x           x               x          x             x   x   x   x      8
  Winning *et al*.\[[@ref35]\]           x           x               x          x                     x   x      6
  Erlich *et al*.\[[@ref25]\]            x           x               x          x             x       x   X      7
  Losche *et al*.(Study 1)\[[@ref50]\]   x           x               x          x                     x   x      6
  Losche *et al*.(Study 2)\[[@ref30]\]   x           x               x          x                     x   x      6
  Eisen *et al*.\[[@ref24]\]             x           x               x          x             x   x   x   x      8
  Kor *et al*.\[[@ref29]\]               x           x               x          x             x   x   x   x      8
  Gross *et al*.\[[@ref27]\]             x           x               x          x                     x   x      6
  Harr *et al*.\[[@ref28]\]              x           x               x          x                     x   x      6
  Valerio-Rojas *et al*.\[[@ref33]\]     x           x               x          x             x   x   x   x      8
  Otto *et al*.\[[@ref31]\]              x           x               x          x                     x   x      6
  Faverio *et al*.\[[@ref26]\]           X           X               X          X                     X   X      6
  Chen *et al*.\[[@ref23]\]              X           X               X          X                     X   X      8
  Tsai *et al*.\[[@ref32]\]              X           X                          X                     X   X      5
  Mazzeffi *et al*.\[[@ref30]\]          X           X               X          X             X   X   X   X      8
  Boyle *et al*.\[[@ref22]\]             X           X               X          X             X       X   X      7
  Al Harbi *et al*.\[[@ref48]\]          X           X               X          X                     X   X      6

RESULTS {#sec1-3}
=======

Our search yielded 1862 articles which were narrowed down to 15 individual full-text articles and 1 conference abstract,\[[@ref22][@ref23][@ref24][@ref25][@ref26][@ref27][@ref28][@ref29][@ref30][@ref31][@ref32][@ref33][@ref34][@ref35][@ref48]\] and included three different studies, out of which two were included in our analysis. This process gave us 17 individual studies with a total of 721,763 patients to include in our analysis \[Supplementary Figure 1\].\[[@ref22][@ref23][@ref24][@ref25][@ref26][@ref27][@ref28][@ref29][@ref30][@ref31][@ref32][@ref33][@ref34][@ref35][@ref48]\]

###### 

Flowchart of search strategy for systematic review

###### 

Click here for additional data file.

All the studies reported event rate, except for 3\[[@ref22][@ref23][@ref31]\] that reported the overall effect using confidence interval (CI) overall effect rather than event rate. This effect was incorporated in the analysis. Among the 17 studies, 16 used aspirin,\[[@ref22][@ref23][@ref24][@ref25][@ref26][@ref28][@ref29][@ref30][@ref31][@ref32][@ref33][@ref34][@ref35][@ref48]\] 10 used clopidogrel,\[[@ref23][@ref25][@ref26][@ref27][@ref29][@ref31][@ref32][@ref33][@ref34][@ref35]\] 5 used ticlopidine,\[[@ref25][@ref28][@ref29][@ref32][@ref33]\] 2 used dipyridamole,\[[@ref25][@ref33]\] and only 1 used anagrelide, cilostazol, and persantine \[[Table 1](#T2){ref-type="table"}\].\[[@ref25]\] Most of our studies included patients on prehospitalization APT except the study by Boyle *et al*.\[[@ref22]\] and Al Harbi *et al*.\[[@ref48]\] which included some patients with *de novo* initiation of APT during hospitalization.

In an effort to stratify or compare patients on APT, 7 studies used the Acute Physiology and Chronic Health Evaluation (APACHE) II score,\[[@ref22][@ref24][@ref25][@ref26][@ref29][@ref34][@ref48]\] 2 studies used the APACHE III score,\[[@ref25][@ref33]\] 2 studies used the Sequential Organ Failure Assessment Score\[[@ref29][@ref35]\] while the rest did not use any of these risk scores \[[Table 1](#T1){ref-type="table"}\].

All-cause mortality {#sec2-6}
-------------------

We found that all-cause mortality was significantly lower in patients on APT (OR: 0.83; 95% CI: 0.70--0.97). There was high heterogeneity in the results; *I*^2^ of 71% \[[Figure 1](#F1){ref-type="fig"}\].

![All-cause mortality](ACA-19-626-g001){#F1}

Duration of hospitalization {#sec2-7}
---------------------------

We also found that while the length of hospital stay was shorter in patients on APT, this effect did not reach statistical significance (SMD, −0.02; 95% CI: −0.11--0.07). There was high heterogeneity in the results; *I*^2^ of 68% \[[Figure 2](#F2){ref-type="fig"}\].

![Duration of hospitalization](ACA-19-626-g002){#F2}

Incidence of acute lung injury/acute respiratory distress {#sec2-8}
---------------------------------------------------------

The incidence of ALI and ARDS was reduced in patients on APT (OR: 0.67; 95% CI: 0.57--0.78) \[[Figure 3](#F3){ref-type="fig"}\]. There was low heterogeneity in these studies; *I*^2^ of 25% \[[Figure 3](#F3){ref-type="fig"}\].

![Incidence of acute lung injury/acute respiratory distress](ACA-19-626-g003){#F3}

Need for mechanical ventilation {#sec2-9}
-------------------------------

The need for mechanical ventilation was less in patients on APT (OR: 0.74; 95% CI: 0.60--0.91). There was low heterogeneity in these studies; *I*^2^ of 21% \[[Figure 4](#F4){ref-type="fig"}\].

![Need for mechanical ventilation](ACA-19-626-g004){#F4}

Sensitivity analysis and cumulative analysis {#sec2-10}
--------------------------------------------

Sensitivity analysis whereby each study was removed individually did not demonstrate significant difference or change in the overall outcomes, except in the analyses of need for mechanical ventilation. When the study by Valerio-Rojas *et al*.\[[@ref33]\] was removed for the outcome, the effect becomes nonsignificant (OR: 0.83; 95% CI: 0.64--1.08). We also carried out a sensitivity analysis by comparing studies on aspirin with studies where patients were on APT other than aspirin, either alone or in combination with aspirin. Comparison of these two groups showed consistent results across all outcomes. Chronological cumulative analysis for each outcome did not find any significant change in the final effect outcomes \[Supplementary Figures 2 and 3\].\[[@ref33]\]

###### 

Cumulative meta-analysis: All-cause mortality; duration of hospitalization; acute lung injury/acute respiratory distress syndrome; need for mechanical ventilation (APT: Antiplatelet therapy, ALI: Acute lung injury, ARDS: Acute respiratory distress syndrome)

###### 

Click here for additional data file.

###### 

Sensitivity analysis for acute lung injury/acute respiratory distress syndrome which reveals that there is a nonsignificant trend toward decreased need for mechanical ventilation after removal of a study by Valerio-Rojas *et al*.\[[@ref33]\] (APT: Antiplatelet therapy)

###### 

Click here for additional data file.

Publication bias {#sec2-11}
----------------

Funnel plot analysis did not show bias for all outcomes. Similar results were observed after quantifying with others' methods (Begg and Mazumdar, Egger, and Duval and Tweedie\'s tests)\[[@ref43][@ref44][@ref45][@ref46]\] \[Supplementary Figures 4 and 5\]. The individual study quality appraisal and the risk of bias are summarized in [Supplementary Table 2](#T3){ref-type="table"}.

###### 

Funnel plots: All-cause mortality (a), duration of hospitalization (b), acute lung injury/acute respiratory distress syndrome (c), need for mechanical ventilation (d)

###### 

Click here for additional data file.

###### 

Tests for publication bias: All-cause mortality (a); duration of hospitalization (b); acute lung injury/acute respiratory distress syndrome (c); need for mechanical ventilation (d)

###### 

Click here for additional data file.

DISCUSSION {#sec1-4}
==========

Our meta-analysis of 17 observational cohort studies with over 720,000 patients revealed that critically ill patients on APT have improved survival when compared to those who do not receive APT. To the best of our knowledge, this is the largest meta-analysis on this topic. A recent meta-analysis by Wang *et al*. aimed to summarize similar evidence but includes only 9 studies as compared to the 17 in this meta-analysis.\[[@ref39]\] This is partly due to a different search strategy as well as our inclusion of conference abstracts and literature published after their cutoff date of November 2015. In our study, the use of APT was also found to be associated with a reduced incidence of ALI/ARDS. Sensitivity analysis revealed that this beneficial effect is not limited to aspirin but rather is consistent across the different antiplatelet drugs used in the included studies. Of note, while bleeding risk or need for transfusion was not assessed using meta-analysis techniques given the small number of studies, an increased risk of these outcomes was not seen in studies that did report these results.\[[@ref24][@ref33][@ref34]\] In fact, a large single-center study reported a decreased risk of bleeding\[[@ref24]\] while another study reported a decreased need for transfusion in patients on APT.\[[@ref33]\]

Previously performed animal studies have shown results similar to our meta-analysis. A study on the effects of clopidogrel on experimentally-induced endotoxemia in mice revealed a trend toward improved survival beyond 48 h.\[[@ref35]\] A study of clopidogrel in polymicrobial sepsis in mice reported decreased thrombocytopenia and end-organ damage.\[[@ref50]\] Blockade of the glycoprotein IIb/IIIa receptor has shown to decrease mortality in rabbits with *Escherichia coli* endotoxin-induced shock.\[[@ref51]\] Another study investigating *E. coli* sepsis in baboon models revealed decreased incidence of microangiopathic hemolysis and renal insufficiency.\[[@ref52]\]

Platelet function is intricately linked to the pathophysiology of sepsis and its complications. Sepsis decreases the hemostatic function of platelets while the capabilities of platelets for molecular expression and cytokine production remain unimpaired and growth factor production is upregulated.\[[@ref53]\] The antimicrobial peptides produced by platelets (known as *defensins*) are bactericidal and essential to the host immune response; however, the resultant inflammatory response may contribute significantly to the microvascular dysfunction characteristic of sepsis.\[[@ref54]\] In addition, during sepsis, there is an increase in phagocytic neutrophil-platelet complexes. These complexes, while aiding in pathogen elimination, also lead to an overwhelming inflammatory response that damages the host. In fact, a study focusing on platelet function in patients with sepsis revealed that while platelet-leukocyte adhesion increased in sepsis, there was a decrease in circulating platelet-neutrophil complexes in patients who died and also in those who had multi-organ dysfunction.\[[@ref55]\] This suggests that there may be peripheral sequestration of these complexes in sepsis, which, in turn, may lead to end-organ damage. Platelet activation also results in hypercoagulation and disseminated intravascular coagulation.\[[@ref56]\]

ARDS is a devastating complication in critically ill patients. The pathophysiology of ARDS is characterized by damage to the alveolar-capillary barrier resulting in increased vascular permeability and influx of protein-rich fluid into interstitial and alveolar membranes.\[[@ref57]\] Platelet activation plays a critical role in this process. Bronchoalveolar lavage fluid from patients with ARDS has excessive quantities of platelet-specific alpha granules, thereby demonstrating the increased platelet activity in these patients.\[[@ref58]\] Activation of platelets leads to adhesion of platelets to the endothelium and release of inflammatory and thrombotic agents along with leukocyte recruitment, edema, and production of neutrophil extracellular traps (NET).\[[@ref59]\] In ARDS, a high concentration of proinflammatory factors in the alveoli can lead to overproduction of NET, which causes direct-tissue injury. They also further activate platelets to promote fibrin deposition and perpetuate the ongoing inflammatory cascade.\[[@ref60][@ref61]\] Our meta-analysis demonstrates a decreased incidence of ALI/ARDS in patients on antiplatelet medications. This is in line with animal studies done previously. Treatment with aspirin reduced transfusion-associated lung injury in mice.\[[@ref37]\] Another study revealed that in rabbit lungs with ALI, blockade of thromboxane A2 (a mediator inhibited by aspirin) eliminated pulmonary hypertension and improved oxygenation.\[[@ref62]\]

There are currently several randomized controlled trials in progress that aim to evaluate the role of APT in sepsis and ARDS. One phase II study aims to randomly assign patients with sepsis/septic shock to aspirin use versus placebo. The primary outcome for this study is a reduction of organ dysfunction. Another study aims to study the effect of aspirin in reducing the severity of ARDS as determined by the oxygenation index. In a similar phase II study, researchers are studying the efficacy of aspirin in preventing ARDS in patients who are at increased risk for ALI.\[[@ref63][@ref64][@ref65]\]

Limitations {#sec2-12}
-----------

There are several limitations to our meta-analysis. First, all the included studies were observational (reflecting the paucity of randomized trials on this topic) and, therefore, prone to bias. Second, this is a meta-analysis performed on study-level data. Third, the definitions and reporting of adverse outcomes and risk of enrolled patients differed across studies. Fourth, most of our studies included patients with prehospital antiplatelet use and as such inferences cannot be extended to new initiation of APT in patients admitted with critical illness. Furthermore, one of the included studies had coexisting NSAID use in both the aspirin group and the control,\[[@ref24]\] which could possibly have influenced the effect on mortality and duration of hospitalization. Previous data are controversial on the use of NSAIDs in sepsis and we cannot be sure of how the inclusion of this study would change the effect size.\[[@ref66]\] Another limitation of our analysis is that the new definition of sepsis (2016) and ARDS (2012) could not be taken into account as it would lead to the removal of a large number of studies still using the older definitions.\[[@ref41][@ref49][@ref67]\] These limitations may explain some of the heterogeneity seen in this meta-analysis for various outcomes. On the other hand, despite these limitations, the consistency of the magnitude, direction of the overall effect, and stability of the results after the sensitivity analyses, in conjunction with the large number of patients studied (the largest patient population studied to-date for a meta-analysis on this topic), support the strength of the conclusions.

CONCLUSION {#sec1-5}
==========

Our meta-analysis shows that critically ill patients receiving APT have a moderately improved survival, decreased incidence of ARDS, and decreased need for mechanical ventilation. These data need to be validated by large randomized controlled trials, which are lacking in this area.
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